Treatment of Pyoderma Gangrenosum.
Neutrophil
Pyoderma gangrenosum
Review
Therapy
Treatment
Ulcer
Journal
Dermatologic clinics
ISSN: 1558-0520
Titre abrégé: Dermatol Clin
Pays: United States
ID NLM: 8300886
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
medline:
1
3
2024
pubmed:
1
3
2024
entrez:
29
2
2024
Statut:
ppublish
Résumé
Pyoderma gangrenosum is a rare neutrophilic dermatosis that results in painful cutaneous ulcers and is frequently associated with underlying hematologic disorders, inflammatory bowel disease, or other autoimmune disorders. Pathogenesis involves an imbalance between proinflammatory and anti-inflammatory mediators, leading to tissue damage from neutrophils. First-line treatment options with the greatest evidence include systemic corticosteroids, cyclosporine, and tumor necrosis factor alpha inhibitors. Other steroid-sparing therapies such as dapsone, mycophenolate mofetil, intravenous immunoglobulin, and targeted biologic or small molecule inhibitors also have evidence supporting their use. Wound care and management of underlying associated disorders are critical parts of the treatment regimen.
Identifiants
pubmed: 38423680
pii: S0733-8635(23)00107-9
doi: 10.1016/j.det.2023.12.002
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
183-192Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have nothing to disclose.